The Board of Trustees of the Leland Stanford Junior University
发明人:
MCLAUGHLIN, Tracey L.,CRAIG, Colleen M.
申请号：
EP16800620
公开号：
EP3297653A4
申请日:
2016.05.23
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.
